TELA Bio, Inc.
TELAHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeTELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and. The company carries a $44.3M market cap, placing it firmly in the micro-cap category. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs.
Market Cap
$44.3M
Beta
1.36
P/E (TTM)
—
P/E (Fwd)
-2.16
EPS (TTM)
$-0.77
EPS (Fwd)
$-0.45
ROE
—
ROA
-33.4%
Cash
$30.4M
Total Debt
$57.9M
Free CF
-$17.7M
52W Change
-33.7%
Annual Financials
Cash vs Debt
Where TELA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TELA finished 14.12% above its 150-day moving average ($0.85) and 12.79% above its 200-day moving average ($0.86). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TELA overbought or oversold?
At the October 20, 2026 close, TELA's RSI(14) was 29.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $30.4M in cash, though total debt stands at $57.9M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$17.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $41.4M (2022) to $80.3M (2025), reflecting a 94% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing TELA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.